Advanced medical research is catching up fast in India. Country’s rapid economic development means that more and more people have high disposable incomes. And they’re willing to shell out money for better living.
In keeping with this new dynamics, several pathbreaking initiatives are happening in medical field. For one, Kolkata will shortly have a full-fledged state-of-the-art liver transplantation facility cum advanced research center inside SSKM Hospital campus.
For another, Reliance Life Science‘s (RLS) biotechnology venture is another great step. RLS has a test that predicts the chances of a woman developing breast cancer in future, that costs Rs.44,000 presently (refer ET, Kolkata, Dec 8).
This is what another ET report (Dec 15) has to say about RLS’ plans:
Reliance’s vision is to script a new paradigm in healthcare with cutting edge predictive diagnostics that will help a person know the chances of developing diseases such as cancer and get therapeutic intervention at the earliest. See the article.
RLS is also in cord blood banking that promises to usher in the latest technology to treat ailments in future. LifeCell, a division of Asia Cryo-Cell Pvt. Ltd, is the only other Indian company to offer cord blood bank service with R&D tie-up with Saneron. See my post, India’s cord blood banking.
All this of course means that more Indians will now have recourse to advanced medicare. The only glitch is the cost, because of which there is no doubt average Indians cannot hope to avail them.
Leave a Reply